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Abstract  
Despite the continuous introduction of innovative therapies for vitiligo, today none of them provide constant and 
excellent results in term of repigmentation. The authors report their experience in treating a localised form of 
vitiligo with a new protocol consisting in the use of a Fraxel Herbium laser, and in the following application of 
topical Latanoprost solution and, one day after, in lesional irradiation with UVA1 laser. 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Vitiligo is an acquired, chronic, cutaneous 
disease, characterised by milky white macules and 
patches, due to the progressive loss of melanocytes 
from the epidermis and its appendages. Because the 
colour contrast between the pigmented skin and the 
cutaneous lesions, vitiligo is an important cause of 
psychological distress and reduction of the life quality 
index so that treating the disease is fundamental 
[1][2]. Vitiligo treatment has two main goals: the first 
one is to halt the disease progression; the second one 
is to induce the lesions’ repigmentation, achieving an 
acceptable cosmetic result. In the last years, several 
therapeutic options, both medical and surgical, have 
been proposed for vitiligo (Table 1) [1][3][5]. 
The aim of this multicenter study was to 
evaluate the efficacy and safety of an innovative 
combination treatment, based on the use of a Fraxel 
Herbium laser, the successive topical application of 
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Latanoprost, and, finally, one day after, by the 
irradiation with UVA - 1 laser. 
Table 1: Main therapeutic options for vitiligo 
MEDICAL THERAPIES Topical and/or systemic corticosteroids 
Phototherapy: oral PUVA, topical PUVA, 
bath - PUVA, sol PUVA, nb - UVB, UVB - 
microphototherapy, UVA - 1 
microphototherapy Excimer laser 
Topical calcineurin inhibitors Topical Vitamin 
D analogues Pseudocatalase 
Topical 5 - Fluoracil 
Topical prostaglandin E2 analogue Systemic 
antioxidants 
Low dose medicine Depigmentation therapy 
Camouflage 
SURGICAL THERAPIES Tissue grafting technique: suction blister 
grafting, split thickness grafting Miniature 
punch grafting Follicular unit grafting 
Smash grafting 
Cellular grafting techniques: non - cultured 
epidermal suspensions, melanocyte culture 
 
 
Patients and Methods 
 
We evaluated 30 subjects (19 female, 11 
male), aged from 20 to 58 years (mean age: 34 
years), who suffered from stable or active forms of 
localised vitiligo vulgaris for more than 18 months and 
less than five years (Table 2).  
In the past six months, none of them had 
been treated for the cutaneous disease. After 
obtaining the informative consent, we decided to treat 
the patients with an innovative therapeutic protocol 
consisting of 3-phases sequential treatment of skin 
lesions. 
Table 2: Distribution of the vitiliginous patches in our patients 
Body part Number of patients 
Trunk 12 
Face 9 
Arms and legs 25 
 
Initially, we treated the vitiliginous lesions with 
a single passage of Fraxel Herbium laser 
(Valseriana® Fraxel Herbium Laser), with a 
wavelength of 1540 nm and an energy level of 1800 
mJ/P. Immediately after obtaining columnar areas of 
epidermal ablation, we applied Latanoprost 0.005% 
(Xalatan®) solution onto each skin lesion (1 drops 
every 2.5*2.5 cm
2
 lesion).  
The day after, we irradiated the skin lesions 
with a UVA1 laser (Laser Alba 355®, the wavelength 
of 355 nm) for 20 minutes. The treatment has been 
repeated every 21 days, for nine months (total 
session). 
For all patients, digital photographs of the 
cutaneous lesions, with normal ambient light and 
Wood’s lamp, have been obtained before the start and 
at each session, for all the treatment period. 
Response to the treatment was determined by 
assigning to each lesion a 0% score before therapy 
and a second percentage value at the end of the 
same lesion, to represent the level of repigmentation. 
Results 
At the end of the treatment, we evaluated the 
repigmentation rate achieved by every single patient 
treated with the innovative protocol. 
Twenty-seven patients (90%) obtained a re-
pigmentation rate higher than 75%, with a medium 
value of 88% (Figure 1). The other three patients 
(10%) achieved a marked improvement of the clinical 
findings with a repigmentation rate between 50-75%. 
 
Figure 1: Progressive rapid repigmentation of Vitiligo patches after 
treatment with Laser Fraxel Herbium, local application of 
Latanoprost solution and UVA1 irradiation 
 
We did not observe any difference in 
repigmentation for lesions with different localisation. 
In any case, we did not observe side effects, 
apart for a transient inflammation (erythema and 
oedema) and itchy sensation in the treated area. 
 
 
Discussion 
 
In this study, we evaluated the treatment of 30 
patient affected by a stable or active form of localised 
vitiligo with a new therapeutic protocol consisting of a 
3 - phases sequential treatment of skin lesions. 
At first, we used a Fraxel Herbium laser 
(Valseriana® Herbium laser) with a wavelength of 
1540 nm and high energy level of 1800 mJ/P. We 
performed only one laser passage for each lesion to 
achieve micro-areas of epidermal ablation [6]. 
Immediately after the laser treatment, we 
applied Latanoprost 0.005% ocular solution (1 
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drop/2.5*2.5 cm
2
 lesion). 
Latanoprost solution is a prostaglandin F2 
alpha (PGF2a) analogue, normally used in the 
treatment of glaucoma. Since the evidence of it's 
periocular and iridal pigmentation side effects, 
Latanoprost has been evaluated for the treatment of 
cutaneous hypo-pigmentation, showing to be effective 
especially in combination with different therapies (e.g. 
phototherapy) [7][8]. 
The day after, we irradiated the skin lesions 
with a focused UVA1 laser with a wavelength of 355 
nm and an energy level of 25 J/cm
2
 (Laser Alba 355®) 
for 20 minutes. 
As the classical UVA1 phototherapy devices, 
Laser Alba 355® acts both stimulating melanocytes 
and inhibiting the immune responses which lead to the 
formation of skin lesions. In detail, it has been shown 
that UVA - 1 can induce the apoptosis of T 
lymphocytes and to inhibit effector T- cells, through 
the direct inhibition of dendritic cells, and through the 
production of interleukin 10 (IL - 10) and the decrease 
of tumour necrosis factor-alpha (TNF - alpha) [9]. 
In contrast to the classical devices, Laser 
Alba 355® has the major advantages that, treating 
only skin lesions, it acts in a safer way reducing the 
side effects due to radiations and achieving better 
aesthetic results regarding less colour contrast 
between a vitiliginous and vitiliginous skin [9][10]. In 
our case, all patients treated with the innovative 
combination therapy achieved good results in term of 
repigmentation (repigmentation rate of 88%) without 
relevant side effects, apart from a transient 
inflammation and erythema. 
In conclusion, the association of Fraxel 
Herbium laser, topical Latanoprost solution and 
focused UVA1 laser seems to provide good clinical 
results in term of repigmentation rate, without side 
effects. 
All the patients were satisfied by the 
innovative protocol treatments, not only for the 
achieved aesthetical results but also for its limited 
number of sessions. 
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